[Skip to Content]
[Skip to Content Landing]
Article
June 12, 1987

Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts

Author Affiliations

From the University of Minnesota Health Sciences Center, Minneapolis.

From the University of Minnesota Health Sciences Center, Minneapolis.

JAMA. 1987;257(22):3082-3087. doi:10.1001/jama.1987.03390220080025
Abstract

Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55%) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3%) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 μmol/L; mean trough, 2.38 μmol/L. Neutropenia occurred in 11 (35%) of 31 patients and in nine (60%) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.

(JAMA 1987;257:3082-3087

×